Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
Delayed Nasdaq  -  04:00 2022-10-04 pm EDT
139.17 USD   +1.07%
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK
AQ
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK (tisotumab vedotin-tftv)
AQ
09/28Zai Lab Strikes Licensing Deal with Nasdaq-listed Seagen for Cervical Cancer Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SVB Securities Adjusts Seagen's Price Target to $152 From $159, Keeps Outperform Rating

08/15/2022 | 05:15am EDT


© MT Newswires 2022
All news about SEAGEN INC.
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
AQ
09/28Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
AQ
09/28Zai Lab Strikes Licensing Deal with Nasdaq-listed Seagen for Cervical Cancer Drug
MT
09/27Zai Lab Signs Exclusive Collaboration, License Agreement With Seagen to Develop, Commer..
MT
09/27Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
BU
09/27Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
CI
09/26Sector Update: Health Care Stocks Fall on Monday
MT
09/26Sector Update: Health Care
MT
09/26Top Midday Gainers
MT
09/26Seagen, Lava Therapeutics Sign License Agreement for Pre-Clinical Asset Targeting Solid..
MT
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 844 M - -
Net income 2022 -639 M - -
Net cash 2022 1 472 M - -
P/E ratio 2022 -40,2x
Yield 2022 -
Capitalization 25 668 M 25 668 M -
EV / Sales 2022 13,1x
EV / Sales 2023 9,47x
Nbr of Employees 2 675
Free-Float 99,1%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 139,17 $
Average target price 183,43 $
Spread / Average Target 31,8%
EPS Revisions
Managers and Directors
Roger D. Dansey Chief Executive & Medical Officer
Todd E. Simpson Chief Financial Officer
Felix James Baker Chairman
Vaughn B. Himes Chief Technical Officer
David W. Gryska Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-9.98%25 668
MODERNA, INC.-50.52%47 331
LONZA GROUP AG-35.56%36 715
IQVIA HOLDINGS INC.-31.56%34 728
ALNYLAM PHARMACEUTICALS, INC.16.05%23 620
CELLTRION, INC.-12.63%16 854